Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 114 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Peripheral Vein Blood draw Clear all
Active, not recruiting Phase 4 Interventional

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

NCT03581877
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions
Alteplase, EKOS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Bay Shore, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational

Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell

NCT02561312
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickling Disorder Due to Hemoglobin S
Interventions
Rapid manual partial exchange transfusion, Simple Transfusion
Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 3 Interventional

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

NCT00002836
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

NCT03325816
View directory record Official record
Conditions
Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Interventions
Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department

NCT02449798
View directory record Official record
Conditions
Vascular Access Complication
Interventions
AccuCath 2.25" BC Intravascular Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

NCT01495572
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Fludarabine, Cyclophosphamide, Aldesleukin, MART-1 Reactive CD8+ PBL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Not applicable Interventional Results available

Validation of Mixed Venous Blood Oxygen Saturation Obtained With a Novel Mathematical Equation

NCT00783952
View directory record Official record
Conditions
Mixed Venous Oxygen Saturation, Tissue Oxygenation
Interventions
Cerebral/Somatic Tissue Oximeter device, Pulmonary artery catheter
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

NCT01413178
View directory record Official record
Conditions
Myeloma
Interventions
Busulfan, Melphalan, Questionnaire, G-CSF, High Dose Melphalan, Stem cell transplant
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational

COVID-19 Respiratory Outcomes Registry

NCT05074875
View directory record Official record
Conditions
Covid19
Interventions
Questionnaires and Patient Reported Outcomes (PROs), Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR), Blood Samples for Biomarkers, High Resolution Computed Tomography, Physical Exam and Vital Signs, Medical Research Council Sum Score, Hand Grip Strength, Spirometry, Diffusing Capacity of Carbon Monoxide, 6 Minute Walk Test, Sit to Stand (STS) Measurement
Other · Diagnostic Test · Genetic
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Timeline
2021 – 2023
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 5, 2026, 5:54 AM EDT
Withdrawn Phase 1 Interventional

Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

NCT03939585
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoproliferative Disorders
Interventions
Cellular therapy product
Biological
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 5, 2026, 5:54 AM EDT
Enrolling by invitation Not applicable Interventional

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

NCT04954625
View directory record Official record
Conditions
Lung Cancer
Interventions
Autologous Blood Patch, Standard of Care (per Physician)
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SPECT/CT Imaging of Skeletal Muscle Perfusion

NCT02791204
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetes Mellitus
Interventions
SPECT/CT imaging following revascularization procedures, SPECT/CT imaging
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational

Effects of Hip Distraction Without a Perineal Post on Venous Blood Flow and Peripheral Nerve Conduction

NCT03417934
View directory record Official record
Conditions
Hip Disease
Interventions
Hip Arthroscopy Procedure
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

NCT00427973
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
cediranib maleate, laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, pharmacological study
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 5, 2026, 5:54 AM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 5, 2026, 5:54 AM EDT
Recruiting No phase listed Observational

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers

NCT07467109
View directory record Official record
Conditions
Intracranial Venous Blood, Brain Cancers, Liquid Biopsy, Evaluate the Safety
Interventions
blood sampling
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function

NCT03062878
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Chemotherapy Effect
Interventions
Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow
Other
Lead sponsor
Carl Ade, M.S., Ph.D.
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD

NCT03490968
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Supervised Exercise, Vascular Assessment
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacology of 17-OHPC in Pregnancy

NCT00409825
View directory record Official record
Conditions
Pregnancy
Interventions
17-OHPC, Blood Draws
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Busulfan and Fludarabine in Patients With AML and MDS

NCT00502905
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 66 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 5, 2026, 5:54 AM EDT
Enrolling by invitation Not applicable Interventional

TruVascular Access - Ultrasound-Guided Vascular Access Study

NCT07798427
View directory record Official record
Conditions
Peripheral Venous Catheterization, Difficult Intravenous Access, Catheterization, Peripheral
Interventions
Ultrasound-Guided Peripheral Vascular Access, Standard Peripheral Vascular Access, Point-of-Care Ultrasound System for Vascular Access Guidance
Procedure · Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
12 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

NCT01176006
View directory record Official record
Conditions
DOCK8 Deficiency
Interventions
Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan), Total Body Irradiation (TBI), Busulfan (Busulfex), Donor peripheral blood stem cell mobiliation and collection, Bone Marrow Harvest Procedure
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

NCT05162638
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
thoracic duct cannulation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 5, 2026, 5:54 AM EDT